Newsroom
Sorted by: Latest
-
Guardant Health e il Policlinico Gemelli lanciano in Italia un servizio di test di biopsia liquida in ospedale
PALO ALTO, Calif. e ROMA--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), azienda leader nel campo della diagnostica oncologica di precisione, oggi ha annunciato il lancio di FPG 360, un servizio di test di biopsia liquida offerto in ospedale presso la Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) a Roma. Questa collaborazione è l'ultima in una serie di partnership tra aziende pubbliche e private formate da Guardant Health con ospedali universitari e di...
-
Guardant Health et le Policlinico Gemelli lancent un service interne de tests de biopsie liquide en Italie
PALO ALTO, Californie et ROME--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq : GH), une société leader dans le domaine de l’oncologie de précision, a annoncé aujourd’hui le lancement réussi de FPG 360, un service interne de test de biopsie liquide à la Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) à Rome, en Italie. Ce partenariat s’inscrit dans le cadre d’une série d’accords public-privé conclus par Guardant Health avec des hôpitaux universitaires et de rec...
-
Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI
BOSTON--(BUSINESS WIRE)--Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a strategic partnership to jointly develop a novel broad-spectrum antibiotic to address critical unmet needs for patients battling life-threatening infections caused by high-p...
-
Samenvatting: Guardant Health en Policlinico Gemelli lanceren eigen testdienst voor vloeibare biopsieën in Italië
PALO ALTO, Calif. & ROME--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), een toonaangevend bedrijf in precisie-oncologie, heeft vandaag de succesvolle lancering aangekondigd van FPG 360, een eigen testdienst voor vloeibare biopsieën bij de Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italië. Deze samenwerking is de nieuwste in een reeks publiek-private samenwerkingen die Guardant Health is aangegaan met vooraanstaande Europese academische en o...
-
BW LPG Limited – Ex Dividend US$0.40 on the Oslo Stock Exchange Today
SINGAPORE--(BUSINESS WIRE)--With reference to the press release dated 2 December 2025 by BW LPG Limited (“BW LPG” or the “Company”, OSE ticker code: “BWLPG.OL”, NYSE ticker code “BWLP”) on key information relating to the cash dividend for Q3 2025, the shares of the Company will be traded ex-dividend on the Oslo Stock Exchange from today and from 12 December 2025 on the New York Stock Exchange. About BW LPG BW LPG is the world’s leading owner and operator of LPG vessels, owning and operating a f...
-
Innate Pharma Releases Its 2026 Financial Calendar
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year financial statements November 5, 2026: Publication of revenue and cash position for 3Q2026 All financia...
-
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrolled at Dr. Vlada Groysman’s site in Birmingham, Alabama. CPUO is an underdiagnosed condition defined as itch lastin...
-
Innate Pharma publie son calendrier financier pour 2026
MARSEILLE--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie aujourd’hui son calendrier financier pour l’année 2026 : 26 mars 2026 : Publication des résultats annuels 2025. 13 mai 2026 : Publication du chiffre d’affaires et de la position de trésorerie au premier trimestre 2026. 21 mai 2026 : Assemblée générale annuelle. 17 septembre 2026 : Publication des résultats semestriels 2026. 5 novembre 2026 : Publication du c...
-
Mitsubishi Electric Named to CDP’s Climate and Water “A List” for the 8th Time and 3rd Consecutive Year
TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that the international nonprofit CDP has once again given Mitsubishi Electric its highest “A List” rankings for both Climate Change and Water Security activities. The top ratings recognize the environmental focus of Mitsubishi Electric’s commercial activities and goals as well as the company’s timely and appropriate information disclosure. Mitsubishi Electric has been named to the A List eight times in both ca...
-
Zilch Lands FCA Payments Licence Marking Major Strategic Growth Milestone
LONDON--(BUSINESS WIRE)--Today, Zilch, the consumer payments platform powering the future of commerce, has announced that it has secured a payments services licence from the Financial Conduct Authority (FCA), further cementing its position as a trusted leader within the market. The licensing marks a significant milestone for Zilch, removing the reliance on third-parties and enabling the business to build more payments methods in-house, develop and bring new products to market even faster and in...